Cell adhesion molecule interaction via carbohydrate recognition domain

The phrase "Cell adhesion molecule interaction via carbohydrate recognition domains" does not refer to a single, specific molecular target or receptor. Instead, it describes a **general mechanism** by which certain proteins—most notably lectins, galectins, collectins, and other glycan-binding proteins—mediate cell-cell or cell-matrix interactions through specialized regions called **carbohydrate recognition domains** (CRDs)[2][10]. These CRDs enable the protein to bind specific sugar moieties on the surfaces of cells or pathogens. Lectins are a well-studied family with CRDs that play key roles in biological recognition phenomena such as blood typing, immune response modulation, pathogen neutralization, and cellular signaling. For example, collectins use their CRD to aggregate and opsonize microorganisms as part of innate immunity[8][9]. Galectins are another family defined by their characteristic CRD; they participate in processes like tumor progression and immune regulation[10]. Because this entry refers to a broad class of molecular interactions rather than an individual therapeutic target or receptor with a canonical name/abbreviation/approved drugs/etc., it is considered **not suitable as an individual drug target entry**. If you seek structured information for drug discovery purposes or database curation, you should instead focus on specific molecules within these families—such as "Galectin 3," "Selectin E," "DC-SIGN," etc.—each of which has its own unique properties. In summary: > The term describes a general mechanism involving various proteins that mediate cell adhesion through carbohydrate recognition domains but does not correspond to one discrete therapeutic target. It is too broad for structured drug-target annotation.[1][2][5]